UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048129
Receipt number R000054794
Scientific Title Effect of Okinawa brown sugar on saliva secretion and vasodilation
Date of disclosure of the study information 2023/06/28
Last modified on 2023/11/24 13:41:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Okinawa brown sugar on saliva secretion and vasodilation

Acronym

Effect of Okinawa brown sugar on saliva secretion and vasodilation

Scientific Title

Effect of Okinawa brown sugar on saliva secretion and vasodilation

Scientific Title:Acronym

Effect of Okinawa brown sugar on saliva secretion and vasodilation

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to examine some kind of promoting effect by test-food intakes on a saliva-secretary function

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Salivary secretion volume by Saxon test

Key secondary outcomes

1. Blood-flow measurement (fingertip and the mouth)
2. Subjective questionnaire


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Consumption of the test food (4 drops/day)

Interventions/Control_2

Consumption of the placebo food (4 drops/day)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Male/female subjects ranging in age from 40 to 64, at informed consent.
(2) Subjects having a subjective symptom of dry mouth.
(3) Subjects who can give informed consent to participate in this study, after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) Subjects who take steadily (not less than three times a week) in the health-specific/functional (e.g., reduced coenzyme Q10-containing)/supplementary/
health foods, which might affect the test results.
(2) Subjects who have taken affecting medicines (e.g., antihistamine/
antidepressant/antihypertensive), and have any difficulty in refraining from taking them during this study.
(3) Subjects who have been to the hospital for dental treatment within three months prior to the consent, or those who are now under the treatment (except taking a periodic dental checkup).
(4) Subjects who have been diagnosed as dry mouth or Sjogren's syndrome.
(5) Subjects with salivary secretion of less than 2 g at the moment of preliminary examination.
(6) Subjects fully realized that their gums are liable to swell up and bleed.
(7) Subjects with excessive alcohol intakes.
(8) Subjects who have previous/current medical history of severe cardiac, hepatic, renal or digestive diseases.
(9) Subjects who have been diagnosed as diabetes, or are now under medical treatment for the disease.
(10) Pregnant, lactating, possibly pregnant women during this study.
(11) Subjects having drug/food allergy.
(12) Subjects who are now under other clinical studies with some kind of medicine and/or health food, or participate in those within four weeks before this study, or are going to took part in those after giving informed consent to take part in this study.
(13) Others who have been determined as ineligible for participation, according to the principal/sub investigator's opinion.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Fumiko
Middle name
Last name Nakamura

Organization

CPCC Company Limited

Division name

Clinical Support Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

TEL

03-6225-9001

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

TEL

03-6225-9001

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

KASUGAI SEIKA

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

Tel

03-6225-9005

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 06 Month 20 Day

Date of IRB

2022 Year 06 Month 17 Day

Anticipated trial start date

2022 Year 06 Month 28 Day

Last follow-up date

2022 Year 08 Month 19 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 06 Month 22 Day

Last modified on

2023 Year 11 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054794


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name